British Columbia Extends Biosimilar Switching To Adalimumab
Follows Launch Of Five Humira Biosimilars In Canada In February
British Columbia has expanded its biosimilar switching program to cover patients being treated with Humira in the Canadian province.
You may also be interested in...
Further Canadian provinces should follow British Columbia and Alberta by adopting biosimilar switching programs, Biosimilars Canada has urged, in the wake of the latest expansion of the British Columbia program to cover adalimumab.
Multiple competitors have now confirmed the launch of Canadian biosimilar versions of the world’s biggest-selling drug, Humira.
Alberta has become the second Canadian province to announce a biosimilar switching program, following the example set by British Columbia earlier this year. The move has been welcomed by Biosimilars Canada but criticized by originator-backed body Crohn’s and Colitis Canada.